We refer to the announcements dated 23 February 2023 and 15 March 2023 in relation to the DRP. Unless otherwise stated, all terms used herein shall have the same meaning as defined in the said announcements.

On behalf of the Board, AmInvestment Bank Berhad (“AmInvestment Bank”) wishes to announce that Bursa Securities had vide its letter dated 20 March 2023, which was received on 21 March 2023, resolved to approve the listing and quotation of up to 13,000,000 new Duopharma Biotech Shares to be issued pursuant to the DRP. The said approval granted by Bursa Securities is subject to the following conditions:

(i) Duopharma Biotech and AmInvestment Bank must fully comply with the relevant provisions under the Main Market Listing Requirements of Bursa Securities pertaining to the implementation of the DRP;

(ii) Duopharma Biotech and AmInvestment Bank to inform Bursa Securities upon completion of the DRP;

(iii) AmInvestment Bank to furnish Bursa Securities with a written confirmation of its compliance with the terms and conditions of Bursa Securities’ approval once the DRP is completed; and

(iv) payment of additional listing fee, if any, based on the final issue price together with a copy of the details of the computation of the amount of listing fees payable.

This Announcement is dated 21 March 2023.